Related Experiment Videos
Immunologic advances in monoclonal antibody therapy: implications for oncology nursing
1Department of Hematology/Oncology Research, University of Chicago Medical Center, IL, USA.
Oncology Nursing Forum
|April 1, 1997
Summary
Monoclonal antibodies (MoAbs) show promise in cancer diagnostics and therapy, with ongoing clinical trials. Oncology nurses require enhanced knowledge to manage MoAb treatments and their toxicities effectively.
Area of Science:
- Immunology and Biotechnology
- Oncology Therapeutics
Background:
- Monoclonal antibodies (MoAbs) are engineered proteins targeting specific antigens.
- Advances in hybridoma technology and gene-splicing enable chimeric MoAb development, reducing immunogenicity.
Purpose of the Study:
- To review monoclonal antibody (MoAb) formation, applications in cancer diagnostics and therapeutics, and implications for oncology nursing.
- To highlight the evolving role of MoAbs in cancer treatment and the need for specialized nursing expertise.
Main Methods:
- Comprehensive literature review of books and journal articles, including clinical research studies.
- Synthesis of data on MoAb technology, clinical trial outcomes, and nursing practice considerations.
Main Results:
- Clinical trials confirm the diagnostic and therapeutic potential of MoAb therapy in oncology.
- Limitations of MoAb therapy include cross-reactivity, antigen heterogeneity, and immune responses.
- Chimeric MoAbs offer improved safety profiles due to decreased immunogenicity.
Conclusions:
- Monoclonal antibodies (MoAbs) are currently used in cancer diagnostics and clinical trials, with future integration into mainstream therapy anticipated.
- Oncology nurses play vital roles in MoAb therapy, necessitating increased understanding of immunologic principles and management of treatment toxicities.